Reduction of tumor burden and stabilization of disease by systemic therapy with anti‐CD20 antibody (rituximab) in patients with primary cutaneous B‐cell lymphoma
Reduction of tumor burden and stabilization of disease by systemic therapy with anti‐CD20 antibody (rituximab) in patients with primary cutaneous B‐cell lymphoma
复制标题
通过抗 CD20 抗体（利妥昔单抗）全身治疗原发性皮肤 B 细胞淋巴瘤患者可减少肿瘤负荷并稳定病情
作者：
L. Heinzerling;Margarete Urbanek;J. Funk;Stefan Peker;O. Bleck;K. Neuber;G. Burg;P. von den Driesch;R. Dummer
原发性皮肤 B 细胞淋巴瘤 (CBCL) 的特点是仅限于皮肤，各种治疗方式后复发率高，预后虽可变但大多良好。
Primary cutaneous B‐cell lymphoma (CBCL) is characterized by restriction to the skin, a high incidence of recurrence after various treatment modalities, and a variable but mostly favorable prognosis.
影响因子：
20.3
作者：
D. Maloney;T. Liles;DK Czerwinski;C. Waldichuk;J. Rosenberg;A. Grillo‐López;R. Levy
通讯作者：
D. Maloney;T. Liles;DK Czerwinski;C. Waldichuk;J. Rosenberg;A. Grillo‐López;R. Levy
DOI：
10.1016/0167-5699(94)90276-3
发表时间：
1994-09-01
期刊：
IMMUNOLOGY TODAY
影响因子：
--
作者：
TEDDER, TE;ENGEL, P
通讯作者：
ENGEL, P